Vascular Targeting Agents
the blood. A modified form of tissue factor was prepared that by itself was inactive in the blood. A VSA was prepared by combining this modified tissue factor with an antibody that was directed to a specific antigen on the tumor epithelium. After binding to the epithelium, tissue factor was activated leading to clot formation and blocking of blood flow through the vessel.
References
1. Brekken, R. et. al. Strategies for vascular targeting in tumors. Int. J. Cancer. 2002 May 23;100 (2): 123-130.
2. Edwards, E. et.al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 2002 Aug 15; 62 (16):4671-7 3. Essler, M. et. al. Molecular specialization of breast vascularure: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. Proc Natl Acad Sci. 2002 Feb 19; 99 (4): 2252-2257. 4. Hallahan, D. et. al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell. 2003 Jan; 3 (1): 63-64. 5. Neri, D. and BicknellR. Tumor vascular targeting. Nature Reviews Cancer. 2005 June; 5 (6):436-446. 6. Oxigene. Vascular Targeting. 2005 7. Peregrine Pharmaceuticals Inc. Vascular Targeting Agents. 2005 8. Scott, J. and Smith, G. Searching for peptide ligands with an epitope library. Science. 1990 Jul 27; 249 (4967): 386-90 9. Tozer, G. et. al. Disrupting tumor blood vessels. Nature Reviews Cancer. 2005 June; 5 (6): 423-435.
Latest Articles